8-K: Cardinal Health Q2 FY26 Earnings Soar, Raises Full-Year Outlook

Cardinal Health reported robust second-quarter fiscal year 2026 results with significant revenue and earnings growth, leading to an upward revision of its full-year non-GAAP EPS guidance.

Summary

• Revenue increased 19% to $65.6 billion in Q2 FY26 from $55.3 billion in Q2 FY25.
• GAAP operating earnings rose 29% to $707 million, and GAAP diluted EPS increased 19% to $1.97.
• Non-GAAP operating earnings grew 38% to $877 million, with non-GAAP diluted EPS up 36% to $2.63.
• All five operating segments achieved at least double-digit segment profit growth.
• Fiscal year 2026 non-GAAP EPS guidance was raised to $10.15 to $10.35, representing 23% to 26% growth.
• Completed $750 million in year-to-date share repurchases for FY26.
• Reached targeted leverage range of 2.75x to 3.25x Adjusted Debt to EBITDA, achieving 3.2x as of December 31, 2025.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive report, driven by strong financial performance across all segments, significant earnings growth, and an upward revision of full-year guidance, indicating robust operational execution and strategic success.

Positives

• Strong revenue growth of 19% to $65.6 billion.
• Significant increase in GAAP operating earnings (29%) and non-GAAP operating earnings (38%).
• Double-digit segment profit growth across all five operating segments.
• Pharmaceutical and Specialty Solutions segment profit increased 29% to $687 million, driven by brand and specialty products, MSO platforms acquisition, and positive generics program performance.
• Global Medical Products and Distribution segment profit increased 106% to $37 million, driven by volume growth and cost optimization initiatives.
• Other segment profit increased 52% to $179 million, driven by growth across at-Home Solutions, OptiFreight Logistics, and Nuclear and Precision Health Solutions.
• Raised fiscal year 2026 non-GAAP EPS guidance to $10.15-$10.35, indicating increased confidence in future performance.
• Completed $750 million in share repurchases year-to-date, returning capital to shareholders.
• Achieved targeted leverage range of 3.2x Adjusted Debt to EBITDA, demonstrating sound financial management.
• Successful acquisition of Solaris Health, expanding The Specialty Alliance's multi-specialty MSO platform.
• Introduction of the ContinuCare Pathway program and a key partnership with Publix Super Markets Inc. for diabetes supply management.
• Earned Great Place to Work Certification in six countries, including the U.S., reinforcing commitment to culture.

Negatives

• Interest and other expense increased due to financing costs related to previously announced acquisitions.
• Global Medical Products and Distribution segment profit was partially offset by an adverse net impact of tariffs.

Risks

• Ability to manage uncertainties associated with the pricing of branded pharmaceuticals and navigate regulatory changes, including those related to pharmaceutical pricing and tariffs.
• Risk of failing to achieve strategic objectives, including the ongoing integration of recent acquisitions and the continued execution of the GMPD Improvement Plan initiatives.
• Competitive pressures in various lines of business, including the risk that customers may reduce purchases or terminate/not renew contracts.
• Risks associated with litigation matters, including Department of Justice investigations focused on potential violations of the Anti-Kickback Statute and False Claims Act.
• Events outside of control, such as weather or geopolitical events, which may impact demand for products or cause supply delays or shortages.
• Performance of the generics program, including the amount or rate of generic deflation and the ability to offset it and maintain financial benefits.

Future Outlook

Cardinal Health raised its fiscal year 2026 non-GAAP diluted EPS guidance to a range of $10.15 to $10.35, reflecting 23% to 26% growth. This updated guidance is driven by raised segment profit growth expectations across all three reporting segments: Pharmaceutical and Specialty Solutions (20% to 22%), Global Medical Products and Distribution (approximately $150 million), and Other (33% to 35%). The non-GAAP effective tax rate is also decreased to a range of 21% to 23%, and diluted weighted average shares outstanding are expected to be 237 million to 238 million.

Management Comments

• "Our strong second-quarter performance reflects at least double-digit segment profit growth across all five of our operating segments."
• "Our ongoing momentum and the teams consistent execution against our strategic priorities gives us confidence to raise our fiscal 2026 outlook."

Industry Context

StockSavvy.ai notes that Cardinal Health's robust performance, particularly in its Pharmaceutical and Specialty Solutions segment, aligns with broader trends of increasing demand for specialty pharmaceuticals and efficient supply chain management in the healthcare sector. The strategic acquisitions and partnerships, like Solaris Health and Publix, demonstrate a proactive approach to expanding market reach and optimizing direct-to-patient solutions, a growing area in healthcare delivery. The strong growth in the "Other" segment, including at-Home Solutions, also reflects the industry's shift towards decentralized care models.

Comparison to Industry Standards

• Cardinal Health's 19% revenue growth significantly outpaces the average growth rates of many established pharmaceutical distributors, which typically see single-digit percentage increases. For example, competitors like McKesson Corporation and AmerisourceBergen (now Cencora) often report revenue growth in the mid-to-high single digits, making Cardinal Health's performance particularly strong in this quarter.
• The 38% increase in non-GAAP operating earnings and 36% increase in non-GAAP diluted EPS demonstrate superior operational leverage and profitability improvement compared to many peers who might struggle with margin pressures due to drug pricing and supply chain complexities.
• The achievement of a 3.2x Adjusted Debt to EBITDA leverage ratio is within the targeted range of 2.75x to 3.25x, indicating sound financial management and a healthy balance sheet, comparable to well-capitalized industry leaders.
• The 106% segment profit growth in Global Medical Products and Distribution, while from a smaller base, suggests successful execution of cost optimization initiatives, potentially outperforming peers facing similar tariff and supply chain headwinds.

Legal Proceedings

• Department of Justice investigations focused on potential violations of the Anti-Kickback Statute and False Claims Act (mentioned as a risk).

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased EPS guidance, and ongoing share repurchase programs, potentially leading to increased share value and returns.
• Employees: Positive impact from the company earning Great Place to Work Certification in six countries, suggesting a strong corporate culture and employee satisfaction.
• Customers: Positive impact from strategic acquisitions like Solaris Health and the ContinuCare Pathway program, which aim to simplify supply management and enhance service offerings.
• Suppliers: Continued strong demand from Cardinal Health's operations could benefit suppliers.
• Creditors: Reaching the targeted leverage range of 3.2x Adjusted Debt to EBITDA indicates sound financial health, which is favorable for creditors.

Next Steps

• A webcast will be hosted on February 5, 2026, at 8:30 a.m. ET to discuss second quarter results and the fiscal year 2026 outlook.
• The slide presentation for the webcast and an audio replay will be available on the Investor Relations page at ir.cardinalhealth.com for 12 months.
• Continued execution of strategic objectives, including the ongoing integration of recent acquisitions and the GMPD Improvement Plan initiatives.

Key Dates

Recommendation

The filing demonstrates exceptional financial performance with significant revenue and earnings growth across all segments, coupled with a raised full-year EPS guidance. Strategic acquisitions and share repurchases further enhance shareholder value. Despite inherent industry risks, the current operational momentum and strong outlook suggest a compelling investment opportunity for seasoned investors.

Keywords

Cardinal Health, CAH, Pharmaceutical Distribution, Specialty Products, Medical Products, Healthcare Logistics, Earnings Report, Q2 FY26, Financial Results, EPS Guidance, Share Repurchase, Acquisitions, Healthcare Supply Chain, Drug Distribution, Medical Devices